logo-loader
viewAusCann Group Holdings Ltd

AusCann Group’s chief operating and financial officer appointed joint company secretary

Quentin Megson will serve jointly in the role with existing company secretary Susan Hunter.

Empty boardroom seats and table
The company aims to produce high-quality and clinically validated cannabinoid medicines

AusCann Group Holdings Ltd (ASX:AC8) has appointed chief operating and financial officer Quentin Megson has been appointed joint company secretary.

He will serve jointly in the role with Susan Hunter, AusCann’s existing company secretary.

Megson joined the medical cannabis company in October 2018 and is an experienced senior executive.

Financial experience

The new joint company secretary has worked in both finance and operational roles for more than 25 years and has held non-executive directorships with several companies.

He holds a Bachelor of Commerce from The University of Western Australia and is a Member of the Institute of Chartered Accountants Australia and New Zealand.

READ: AusCann Group DayaCann joint venture to commence crop cultivation with Khiron

AusCann is an Australian-based pharmaceutical company that aims to produce high-quality, economical and clinically validated cannabinoid medicines.

The company brings together leading expertise and operations across all aspects of the medical cannabis value chain.

This begins with cultivation and production and extends through to manufacture and distribution of products.

READ: AusCann Group acquires R&D facility to develop cannabinoid product pipeline

Last month AusCann acquired a 7,300 square metre research and development (R&D) facility in Perth, Western Australia.

The facility, which was purchased for $5.25 million, will focus on AusCann’s cannabinoid pharmaceutical product pipeline, supporting development of innovative formulations and dose forms.

AusCann will invest up to $6 million over time to customise and fit out the site for use during 2019.

The acquisition and upgrade costs will be funded from AusCann’s cash balance which was more than $40 million prior to the acquisition.

Quick facts: AusCann Group Holdings Ltd

Price: 0.27 AUD

ASX:AC8
Market: ASX
Market Cap: $85.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of AusCann Group Holdings Ltd named herein, including the promotion by the Company of AusCann Group Holdings Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Auscann targeting pain management with Australian cannabinoid products

Elaine Darby, managing director of Auscann Group Holdings Ltd (ASX:AC8), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney. Auscann is continuing to make steady progress towards releasing its first medicinal cannabis products during the financial year 2019....

on 6/9/18

2 min read